secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0001654954-24-010213
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences approves 1:50 reverse stock split, increases authorized shares to 1B, appoints new Head of Finance
--------------------------------------------------------------------------------

- Senior Director of Finance Irina Pestrikova resigned Aug 7; Richard Jacroux appointed Head of Finance & principal financial officer on Aug 8.
- Stockholders approved increase in authorized common shares from 80M to 1B; amendment filed Aug 8.
- Board set reverse stock split ratio at 1-for-50, authorized by stockholders (range 1:20 to 1:50).
- At Aug 6 annual meeting: all five director nominees elected; say-on-pay, warrant issuance, and auditor ratification passed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424010213/0001654954-24-010213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424010213/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-010213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer